文献速递支持与姑息治疗

抗PD-1抗体在合并自身免疫或炎症性疾病肿瘤患者中的安全性与疗效

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
PubMed 文献 · Eur J Cancer · 2018-01-10

基于REISAMIC登记的前瞻性研究,分析45例合并53种自身免疫或炎症性疾病(AID)的肿瘤患者接受抗PD-1抗体治疗。AID患者无免疫相关不良事件(irAE)生存期显著短于无AID患者(中位5.4个月 vs 13个月,p=2.1×10-4),但总生存期和客观缓解率无显著差异。

要点

  • 合并AID的肿瘤患者接受抗PD-1抗体治疗时irAE风险显著增加。
  • AID患者与无AID患者的总生存期和客观缓解率无显著差异。

核心结论

  • 合并AID的肿瘤患者接受抗PD-1抗体治疗时irAE风险显著增加。
  • 抗PD-1抗体在AID患者中的疗效与无AID患者相当。

研究设计与样本

  • 前瞻性研究,基于REISAMIC登记中接受ICI治疗且发生≥2级irAE的患者。
  • 共纳入45例合并53种AID的肿瘤患者,癌种包括黑色素瘤(n=36)、非小细胞肺癌(n=6)和其他(n=3)。

主要发现

  • 20例出现irAE的患者中15例维持了抗PD-1抗体治疗。
  • AID患者无irAE生存期中位5.4个月,显著短于无AID患者的13个月(p=2.1×10-4)。
  • AID组与无AID组的总生存期(p=0.38)和客观缓解率(p=0.098)无显著差异。

关键数值与推荐

  • 最常见预存AID:白癜风(n=17)、银屑病(n=12)、甲状腺炎(n=7)、干燥综合征(n=4)、类风湿关节炎(n=2)。
  • AID患者无irAE生存期中位5.4个月,无AID患者中位13个月,p=2.1×10-4。
  • 总生存期比较p=0.38,客观缓解率比较p=0.098。

临床怎么用

  • 对合并AID的肿瘤患者使用抗PD-1抗体时,应加强irAE监测与管理。
  • 预存AID不应作为排除抗PD-1抗体治疗的绝对依据,因疗效与无AID患者相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Patients with autoimmune or inflammatory disease (AID) are susceptible to immune-related adverse events (irAEs) when treated with immune check-point inhibitors (ICIs). We decided to analyse the safety and effectiveness of anti-PD-1 antibodies in AID patients and look for an association between the presence of pre-existing AID and the clinical outcome. METHODS: In a prospective study of the REISAMIC registry of grade ≥2 irAEs occurring in ICI-treated patients, we studied the associations between pre-existing AID on one hand and irAE-free survival, overall survival and best objective response rate on the other. RESULTS: We identified 45 patients with 53 AIDs in REISAMIC. The cancer diagnoses included melanoma (n = 36), non-small-cell lung cancer (n = 6) and others (n = 3). The most frequent pre-existing AIDs were vitiligo (n = 17), psoriasis (n = 12), thyroiditis (n = 7), Sjögren syndrome (n = 4) and rheumatoid arthritis (n = 2). Twenty patients (44.4%) presented with at least one irAE: eleven of these were associated with a pre-existing AID ('AID flare'). Treatment with anti-PD-1 antibodies was maintained in 15 of the 20 patients with an irAE. The IrAE-free survival time was significantly shorter in AID patients (median: 5.4 months) than in AID-free patients (median: 13 months, p = 2.1 × 10-4). The AID and AID-free groups did not differ significantly with regard to the overall survival time and objective response rate (p = 0.38 and 0.098, respectively). CONCLUSION: In patients treated with anti-PD-1 antibody, pre-existing AID was associated with a significantly increased risk of irAEs. Our results indicate that cancer treatments with anti-PD-1 antibodies are just as effective in AID patients as they are in AID-free patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018. PMID: 29331748. doi:10.1016/j.ejca.2017.12.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。